Active — Not RecruitingPhase 2

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

United States10 participantsStarted 2017-04-15

Plain-language summary

Benralizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, benralizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental drug in this study.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. A biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation;
✓. Neuropathy, mono or poly (motor deficit or nerve conduction abnormality);
✓. Pulmonary infiltrates, non-fixed;
✓. Sino-nasal abnormality;
✓. Cardiomyopathy (established by echocardiography or MRI);
✓. Glomerulonephritis (haematuria, red cell casts, proteinuria);
✓. Alveolar haemorrhage (by bronchoalveolar lavage);
✓. Palpable purpura;

What they're measuring

All adverse events will be reported by count of events (safety and tolerability )

Timeframe: Up to 12 months

Trial details

NCT IDNCT03010436

SponsorNational Jewish Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-07-25

View on ClinicalTrials.gov More Asthma trials